U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
IRVINE, Calif., April 05, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Kitov Pharmaceuticals Holdings Ltd (“Kitov” or the “Company”) (Nasdaq:KTOV). Investors who purchased Kitov American Depositary Receipts (“ADRs”) pursuant to the Company’s initial public offering on or about November 20, 2015 (the “IPO”) and/or between November 20, 2015 and February 3, 2017 inclusive (the “Class Period”), are encouraged to contact the Firm before the April 10, 2017 lead plaintiff motion deadline.
If you purchased Kitov shares during the IPO or Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the Complaint, Kitov made false and/or misleading statements and/or failed to disclose that the Company and its CEO Isaac Israel, published misleading information concerning the conduct of the Company’s clinical trials for its lead drug candidate, KIT-302, and consequently, Kitov’s public statements were materially false and misleading at all relevant times. On February 6, 2017, Calcalist, an Israeli publication, reported that Isaac Israel was detained and questioned by the Israeli Securities Authority for allegedly publishing misleading information about the Company’s recent clinical trial.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contacts Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
